Mecapegfilgrastim, Adebrelimab and Chemotherapy Before Surgery for Stomach Cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests whether adding two drugs (mecapegfilgrastim and adebrelimab) to standard chemotherapy before surgery can help treat advanced stomach or gastroesophageal junction cancer that has not yet spread. The goal is to shrink the tumor and improve surgical outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have stomach or gastroesophageal junction cancer that is locally advanced (stage T3-4a/N+M0) and has not spread to other organs.
- Your tumor is HER2-negative or its HER2 status is unknown.
- You have not received any previous cancer treatment (like chemotherapy or immunotherapy).
- You are in good enough health to undergo surgery and have normal blood, heart, kidney, and liver function.
- You weigh more than 40 kg (about 88 pounds) and have a BMI over 18.5.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of low-dose radiation, chemotherapy, and an immunotherapy drug (AK112) for people with advanced stomach or gastroesophageal junction cancer that has progressed after first-line treatment. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
This trial is testing a combination of three medicines—an immunotherapy (anti-PD-1), an immune booster (thymalfasin), and a chemotherapy regimen (SOX)—given before surgery to shrink stage III stomach or gastroesophageal junction cancer and improve outcomes.
This trial tests two new immunotherapy drugs (SHR-A1811 and SHR-A1701) given before surgery to treat advanced stomach or gastroesophageal junction cancer. The goal is to shrink the tumor and help your immune system fight the cancer before surgical removal.
This trial tests a drug called adebrelimab along with chemotherapy and radiation before surgery for stomach or gastroesophageal junction cancer that has spread locally or has limited spread. It aims to see if this combination can help make the tumor removable and improve outcomes.
This trial tests a combination of chemotherapy (FLOT), an immunotherapy drug (pembrolizumab), and short-course radiation before surgery for gastroesophageal junction cancer. The goal is to see if this approach improves outcomes.
This trial tests a combination of chemotherapy drugs (nab-paclitaxel, oxaliplatin, and S-1) plus an immunotherapy drug (sintilimab) given before surgery for younger people (ages 16 to 45) with stomach or gastroesophageal junction cancer that can be removed. The goal is to see if this approach shrinks tumors and improves outcomes.
Hear when a new GC/GEJC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.